• nVNS therapy, dispensed via a real-world primary care clinic, was successfully utilised to treat patients with multiple medically unexplained symptoms • Self-reported health outcomes improved for approximately 60% of the patients completing the EQ-5D-5L questionnaire • Patients reported less pain and discomfort, improved ability to perform their usual daily activities, and lower levels of anxiety and depression after attending the clinic and adopting gammaCore • Healthcare resource consumption was significantly reduced following this novel clinical intervention • The initial results of this study are very positive. Further work is required to elucidate the full potential for this clinic to improve the care of these mutimorbid patients and generate healthcare resource savings References 1. Multimorbidity: clinical assessment and management. NICE guidelines [NG56]
Introduction

Multimorbidity
• Guidelines published by The National Institute for Health and Care Excellence (NICE) describe the need to optimise the care received by patients with multimorbidity 1 • The aim of these guidelines is to improve patient quality of life and reduce unnecessary clinical appointments and unplanned care
Medically Unexplained Symptoms
• Approximately 25% of all GP consultations, and 25% of all hospital referrals are generated by 10% of the 18 to 70 year old patient population with multiple "medically unexplained symptoms" or "functional disorders" • These patients suffer from 3 or more concurrent diagnoses falling into the following categories; primary headache disorders, gastric motility disorders, anxiety, depression, and widespread chronic pain 2 Non-invasive vagus nerve stimulation
• Non-invasive vagus nerve stimulation (nVNS) has been shown to be an effective treatment of primary headache disorders 3 and may have the potential to treat multiple medically unexplained symptoms
Objective
Establish whether non-invasive vagus nerve stimulation therapy (gammaCore®, electroCore LLC, New Jersey, USA) could be utilised as a treatment option in the management of medically unexplained symptom multimorbidity.
Methods
Patient identification
• A clinical pharmacist interrogated GP practice computer systems in 7 primary care practices in the UK to identify 18-70 year old patients diagnosed with 2 or more functional diagnoses of the following conditions: primary headache, gastric motility disorders, anxiety & depression, chronic pain, sinobronchial symptoms, tinnitus, epilepsy or insomnia • The pharmacist gained approval from the lead GP to send a written invitation offering eligible patients the opportunity to attend a multimorbidity clinic. In total 2206 invites were sent to eligible patients. Patients were not obliged to attend
Clinic design
• Patients who voluntarily attended the first clinic were asked to complete a health related quality of life questionnaire (EQ-5D-5L and EQ-VAS) • Patients willing to use gammaCore (gC) as an adjunct to their current treatment regimen were trained to use the device, given a device to take home, and advised to administer 3 bilateral nVNS doses per day (Figure 1 ., 12 minutes total therapy time per day) • Two further face-to-face clinics were conducted to check stimulation technique, adherence to therapy and to address any questions that patients may have
Patient reported outcomes and impact on healthcare resource
• Patients were asked to provide EQ-5D-5L scores on a monthly basis. Monthly scores were compared to those collected during the first clinic in order to measure any changes in patient quality of life • Changes in healthcare resource were calculated by counting the number of GP consultations attended and the number of referrals made, during individual time-matched periods before and after gC initiation
Statistical analyses
• Descriptive statistics were used to compare patient reported health outcomes before and after gC initiation. Differences in the average number of GP consultations attended and referrals made were calculated using a paired parametric t Test
Results
Patients
• Sending 2206 postal invitations resulted in 422 patients attending the first clinic. 354 of these patients were deemed suitable to be offered the use of gC therapy • In total 233 patients attended both the first and second face-to-face clinic, showing good activation levels and compliance with the gC regimen • At 8 and 40 weeks post gC initiation, 145 and 61 patients respectively, reported their EQ-5D-5L health outcomes (Table 1.) • 179 (77%) patients used gC for 3 months or more, with 134 (58%) patients continuing therapy beyond 6 months
Patient reported health outcomes
Results on the impact of gC on patient reported health outcomes have been generated from all available data sets. At weeks 8 and 40 there were 145 and 61 patients respectively who provided EQ-5D-5L data.
• At 8 and 40 weeks post gC initiation, 66% and 59% of patients respectively were experiencing an improvement in self-reported health status when EQ-5D-5L profiles were compared to pre-gC profiles ( Figure 2 .) • Improvements in EQ-5D-5L dimensions were observed in patients' levels of Pain/discomfort, ability to perform usual activities, and levels of Anxiety/depression ( Table 2 .) • Mean EQ-VAS scores reported at week 8 and week 40 were significantly higher than those reported prior to gC initiation (P< values derived from an ANOVA with Dunnett's multiple comparison test, Data from all 233 patients who attended the first two clinics has been used to calculate the impact of gC on health care resource utilisation.
• There was a significant 19% reduction in the mean number of GP appointments attended by patients after gC initiation, compared to a matched period prior to the first clinic ( Over a one-year time horizon comparing nVNS + standard care with standard care alone, an ICER of £13,368 per QALY is estimated (Table 2) . nVNS would, therefore, be considered cost-effective at a £20,000 per QALY threshold. Cost savings are generated from a reduction in GP consultation costs and a reduction in referrals to secondary care, Non-invasive vagus nerve stimulation (nVNS), delivered via the therapeutic medical device gammaCore ® (electroCore LLC, New Jersey, United States of America), has been shown to be efficacious in the treatment of primary headache disorders [1] . Previous analyses have demonstrated that nVNS delivered by gammaCore (gC) is a cost-effective treatment in patients with cluster headaches [2] .
nVNS improves the quality of life for patients suffering with multiple, medically unexplained, functional disorders such as headache, gastric mobility disorders, depression and anxiety [3] . 
RESULTS
A decision analytic model was developed in Microsoft Excel to estimate the cost-utility of nVNS over both a one-year and two-year time horizon. The model utilised EQ-5D-5L and healthcare resource data collected from a cohort study set in nVNS primary care clinics within the NHS designed to treat multi-morbid patients (n=233) [3] . Included patients had two or more diagnoses codes under the following disorders: headache, anxiety or depression, gastrointestinal disorders, pain, sinobronchial symptoms, tinnitus or epilepsy.
Resource use data were combined with unit cost data to determine the cost implications of multi-morbid patients either with or without the use of nVNS. Costs included within the model comprised primary care visits; prescription costs; secondary care visits and device related costs. Device costs were applied for the duration during which patients remained on treatment. Participants were instructed to use the device bilaterally, three times a day.
Utility scores were elicited using the EQ-5D-5L scores collected at baseline and every four weeks during the clinical study and applying Kaplan-Meier methods to account for censoring. Utility at baseline was used in the standard care arm of the model. The key input parameters are shown in Table 1 .
The primary outcome of the model was an estimated incremental cost per quality adjusted life year (QALY) comparing nVNS + standard care, to standard care alone over a 12 month period. Deterministic sensitivity analyses (DSA) were conducted to assess the impact of bias on the results of the model. Exploratory analysis were also conducted by extrapolating the data over a two-year time horizon.
Based on preliminary data, from a UK NHS perspective, nVNS + standard care is estimated to be cost-effective at a £20,000 per QALY threshold compared to standard care alone in patients with functional multi-morbidities. The use of comparative clinical data within the model would strengthen these conclusions. 
